XML 35 R23.htm IDEA: XBRL DOCUMENT v3.6.0.2
Commitments and Contingencies (Tables)
 12 Months Ended
Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
Schedule of lease payments

The Company is committed to lease payments as follows:

 

Fiscal year ending September 30,   Amount  
2017   $ 112,189  
2018     112,189  
2019     56,094  
    $ 280,472  
Schedule of purchase warrants outstanding

A summary of the Company’s share purchase warrants outstanding is presented below:

 

    Number of Shares     Weighted
Average
Exercise Price		  
Balance, October 1, 2014     18,728,910     $ 1.59  
Expired     (62,500 )   $ 1.40  
Exercised     (15,468,520 )   $ 1.43  
Issued     1,075,000     $ 0.76  
Balance, September 30, 2015     4,272,890     $ 2.11  
Exercised     (2,463,581 )   $ 1.67  
Balance, September 30, 2016     1,809,309     $ 2.70  
Schedule of exercisable share purchase warrants outstanding

At September 30, 2016, the Company had 1,809,309 currently exercisable share purchase warrants outstanding as follows:

 

Number     Exercise Price     Expiry Date
  1,462,180     $ 3.00     July 5, 2018
  30,000     $ 4.00     February 24, 2019
  277,127     $ 1.20     March 13, 2019
  1,252     $ 1.68     March 13, 2019
  31,250     $ 1.24     May 31, 2019
  7,500     $ 1.04     May 31, 2019
  1,809,309              
Schedule of outstanding stock purchase options

A summary of the status of Company’s outstanding stock purchase options for the years ended September 30, 2016 and 2015 is presented below:

 

    Number of
Shares		     Weighted
Average
Exercise Price		     Weighted
 Average Grant
Date fair value		  
Outstanding at October 1, 2014     792,500     $ 2.82          
Forfeited     (67,500 )   $ 12.00          
Granted     1,097,500     $ 2.02     $ 1.66  
Outstanding at September 30, 2015     1,822,500     $ 2.00          
Forfeited     -     $ -          
Granted     2,401,500     $ 5.22     $ 4.38  
Expired     (25,000 )   $ 14.68          
Outstanding at September 30, 2016     4,199,000     $ 3.76          
Exercisable at September 30, 2016     2,290,716     $ 2.41          
Exercisable at September 30, 2015     825,002     $ 1.78        
Schedule of stock options outstanding

At September 30, 2016, the following stock options were outstanding:

 

Number of Shares               Aggregate     Remaining  
      Number     Exercise         Intrinsic     Contractual  
Total     Vested     Price     Expiry Date   Value     Life (yrs)  
  500,000       500,000     $ 1.60     July 5, 2023     1,015,000       6.76  
  75,000       50,000     $ 1.20     May 7, 2024     182,250       7.60  
  125,000       62,500     $ 1.32     May 8, 2024     288,750       7.60  
  718,750       479,170     $ 0.92     April 2, 2025     1,947,813       8.50  
  50,000       20,834     $ 1.44     June 8, 2025     109,500       8.69  
  50,000       16,667     $ 1.76     June 15, 2025     93,500       8.71  
  278,750       116,146     $ 5.04     September 18, 2025     -       8.97  
  1,500       1,500     $ 5.64     September 30, 2025     -       9.00  
  31,250       10,416     $ 5.68     October 2, 2025     -       9.00  
  25,000       8,333     $ 8.98     October 16, 2025     -       9.04  
  1,500       1,500     $ 5.57     December 31, 2025     -       9.25  
  1,500       -     $ 4.90     March 31, 2026     -       9.50  
  1,500       1,500     $ 5.66     April 27, 2026     -       9.57  
  50,000       12,121     $ 4.09     May 18, 2026     -       9.63  
  1,500       -     $ 6.11     June 30, 2026     -       9.75  
  379,625       -     $ 6.26     July 5, 2026     -       9.76  
  861,429       -     $ 7.06     July 18, 2026     -       9.80  
  40,000       3,333     $ 3.06     September 7, 2026     22,800       9.94  
  1,006,696       1,006,696     $ 3.28     September 22, 2026     352,344       9.98  
  4,199,000       2,290,716                 $ 4,011,956      
Schedule of general and administrative expenses and research and development expenses

These amounts have been included in general and administrative expenses and research and development expenses on the Company’s statement of operations as follows:

 

    2016     2015     2014  
General and administrative   $ 2,903,220     $ 413,979     $ 27,925  
Research and development     1,549,047       -       -  
    $ 4,452,267     $ 413,979     $ 27,925  
Schedule of weighted average assumptions for fair value of each option award

The fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:

 

    2016     2015     2014  
Risk-free interest rate     1.28 %     1.63 %     2.27 %
Expected life of options (years)     5.88       6.30       6.81  
Annualized volatility     114.75 %     98.41       89.19  
Dividend rate     0.00 %     0.00 %     0.00 %